Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators

US9796733B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Brian T. Campbell · Souderton, US
• Guizhen Dong
• Joie Garfunkle · Metuchen, US
• Alexander Kim · Levittown, US
• Olga Ornoski · Teaneck, US
• Dann Parker · Cranford, US
• Subharekha Raghavan · Teaneck, US
• Libo Xu · Bound Brook, US
• Zhiquang Yang · Westfield, US

Key dates

• Filing date: May 29, 2015
• Grant date: Oct 24, 2017
• Expiry date: May 29, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P11/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of Formula II or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula II, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula II or a pharmaceutically acceptable salt thereof.